.....
In addition to the threat of generic competition, Vancocin also could face competition from a branded product in the future. Last week, Optimer Pharmaceuticals Inc. of San Diego announced study results that the company said shows its experimental gastrointestinal infection drug, OPT-80, was more effective than Vancocin in terms of cure rates and reductions in relapse rates.
Optimer’s drug is still in clinical testing and is not on track to hit the market, pending FDA approval, until the second half of 2010.
http://philadelphia.bizjournals.com/philadelphia/stories/2008/12/01/story15.html?b=1228107600^1740182&t=printable